Mark Smith, MD
Nephrology · Anchorage, AKNPI 1861479651
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $99,827 of the $150,386 with a category attached, or 66.4%. Bayer accounts for 62.0% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2022 at $78,873 and has fallen 69.7% since, to $23,928 in 2025.
Across 384 payments — averaging $391.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$93K
- Otsuka America Pharmaceutical, Inc.$30K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$10K
- Vifor Pharma, Inc.$10K
- Novo Nordisk AS$2K
- Pfizer$780
- plus $4K from 24 others
Across 154 payments — averaging $3035.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$384K
- Novo Nordisk AS$47K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$20K
- Akebia Therapeutics Inc$16K
- Amgen$547
What the payments were for
- Consulting fees$33,80222%
- Speaking & faculty fees$99,82766%
- Travel & lodging$8,9266%
- Food & beverage$7,5985%
- Education$2340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 122 | $93,230 |
| Otsuka America Pharmaceutical, Inc. | 42 | $30,489 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 17 | $10,251 |
| Vifor Pharma, Inc. | 33 | $9,584 |
| Novo Nordisk AS | 1 | $2,475 |
| Pfizer | 1 | $780 |
| AstraZeneca(2 entities) | 43 | $695 |
| Mallinckrodt Hospital Products Inc. | 13 | $396 |
| Novartis | 18 | $359 |
| Aurinia Pharma U.S., Inc. | 11 | $294 |
| Calliditas Therapeutics US Inc. | 8 | $278 |
| OPKO Pharmaceuticals, LLC | 11 | $216 |
| Travere Therapeutics, Inc. | 14 | $178 |
| Amgen(2 entities) | 8 | $172 |
| Fresenius USA Marketing, Inc. | 8 | $136 |
| GSK | 8 | $128 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $125 |
| Daiichi Sankyo Inc. | 6 | $115 |
| AbbVie | 1 | $108 |
| Boehringer Ingelheim | 4 | $71 |
| Kyowa Kirin, Inc. | 1 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $50 |
| Akebia Therapeutics Inc | 2 | $42 |
| Mallinckrodt Enterprises LLC | 2 | $38 |
| Novo Nordisk | 1 | $32 |
| Shire North American Group Inc | 2 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Ardelyx, Inc. | 1 | $13 |
| Boston Scientific | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few nephrology providers in Alaskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KerendiaFinerenone | 189 | $182,756 |
| FarxigaDapagliflozin Propanediol | 139 | $129,497 |
| VeltassaPatiromer Calcium Sorbitex | 88 | $108,615 |
| JardianceEmpagliflozin | 63 | $52,144 |
| Cinacalcet Hcl | 23 | $14,327 |
| LokelmaSodium Zirconium Cyclosilicate | 15 | $9,189 |
| Eplerenone | 81 | $7,132 |
| Sevelamer Carbonate | 92 | $6,366 |
| Mycophenolate Mofetil | 11 | $4,537 |
| Telmisartan | 110 | $3,559 |
| Colchicine | 13 | $3,456 |
| Losartan Potassium | 146 | $1,896 |
| Spironolactone | 231 | $1,802 |
| Potassium Citrate ErPotassium Citrate | 14 | $1,569 |
| Valsartan | 28 | $1,236 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerKerendia | $93,230 | $182,756189 claims |
| AstraZenecaFarxiga, Lokelma | $695 | $138,687154 claims |
| Boehringer IngelheimJardiance | $71 | $52,14463 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few nephrology providers in Alaskaon file to place this against a meaningful peer group, so we don't.
Other nephrology in Anchorage
- Andrzej MaciejewskiAnchorage$60K
- Jeremy GitomerAnchorage$21K
- Stefano EmiliAnchorage$2K
- Shuang Ying BaoAnchorage$893
- Leslie GlasgowAnchorage$834
- Lisa RobertsAnchorage$681
- Rahul AbrahamAnchorage$485
- Osman YilmamAnchorage$412
- Chadwick BarnesAnchorage$224
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.